These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36305267)

  • 1. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
    Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
    Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
    Castellano GM; Zeeshan S; Garbuzenko OB; Sabaawy HE; Malhotra J; Minko T; Pine SR
    Mol Cancer Ther; 2022 Sep; 21(9):1381-1392. PubMed ID: 35732569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of lysine (K)-specific demethylase 2B KDM2B inhibits glycolysis and induces autophagy in lung squamous cell carcinoma cells by regulating the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.
    Xie Z; Li H; Zang J
    Bioengineered; 2021 Dec; 12(2):12227-12235. PubMed ID: 34783291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GNA13 promotes the proliferation and migration of lung squamous cell carcinoma cells through regulating the PI3K/AKT signaling pathway.
    Na J; Zhou W; Yin M; Hu Y; Ma X
    Tissue Cell; 2022 Jun; 76():101795. PubMed ID: 35413491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
    Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
    PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.
    Shen C; Shyu DL; Xu M; Yang L; Webb A; Duan W; Williams TM
    Mol Cancer Res; 2022 Mar; 20(3):425-433. PubMed ID: 34810212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (+)-Usnic Acid Induces ROS-dependent Apoptosis via Inhibition of Mitochondria Respiratory Chain Complexes and Nrf2 Expression in Lung Squamous Cell Carcinoma.
    Qi W; Lu C; Huang H; Zhang W; Song S; Liu B
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
    Wang Q; Zhang X; Song X; Zhang L
    Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
    Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
    Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.
    Quintanal-Villalonga A; Taniguchi H; Zhan YA; Hasan MM; Chavan SS; Meng F; Uddin F; Allaj V; Manoj P; Shah NS; Chan JM; Ciampricotti M; Chow A; Offin M; Ray-Kirton J; Egger JD; Bhanot UK; Linkov I; Asher M; Roehrl MH; Ventura K; Qiu J; de Stanchina E; Chang JC; Rekhtman N; Houck-Loomis B; Koche RP; Yu HA; Sen T; Rudin CM
    J Hematol Oncol; 2021 Oct; 14(1):170. PubMed ID: 34656143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
    Aggarwal S; John S; Sapra L; Sharma SC; Das SN
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):451-461. PubMed ID: 30519710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth and Viability of Cutaneous Squamous Cell Carcinoma Cell Lines Display Different Sensitivities to Isoform-Specific Phosphoinositide 3-Kinase Inhibitors.
    Mannella V; Boehm K; Celik S; Ali T; Mirza AN; El Hasnaouy M; Kaffa A; Lyu Y; Kafaei Golahmadi D; Leigh IM; Bergamaschi D; Harwood CA; Maffucci T
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer.
    Deng H; Chen Y; Wang L; Zhang Y; Hang Q; Li P; Zhang P; Ji J; Song H; Chen M; Jin Y
    Cell Death Dis; 2023 Oct; 14(10):652. PubMed ID: 37802999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.